



Press Release

November 16, 2005

Uppsala, Sweden

Gyros awarded Frost & Sullivan Technology of the Year Award

Gyros announced today that it has been awarded Frost & Sullivan's 2005 Excellence in Technology of the Year Award in the field of laboratory automation for Gyrolab™ automated system (Gyrolab Workstation).

Frost & Sullivan's Excellence in Technology Award is given to the company that has pioneered the development and introduction of an innovative technology into the market; a technology that has either impacted or has the potential to impact several market sectors. The award recognizes the company's successful technology development that is expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. It also recognizes the overall technical excellence of the company and its commitment towards technology innovation.

Gyrolab Workstation enables researchers to generate more information from fewer samples and improves lab performance by streamlining the many steps of conventional applications into single, nanoliter scale procedures. The fully automated solution significantly shortens analysis time and reduces sample and reagent consumption. The technology is currently used for protein analysis applications within research, drug discovery and development, and in vitro diagnostics for medical applications in collaboration with partners.

Commenting on the award, Jan Würtz, CEO & President of Gyros AB said; "This is a fantastic achievement and we are obviously delighted to receive the award. It is especially satisfying to know that the significant and unique benefits offered by Gyros technology are becoming more widely recognized in what is a very competitive market place."

“It is also a great reward for everybody within the company who have worked so hard in developing the technology and successfully bringing it to market”, added Mr. Würtz.

More information about Gyrolab Workstation:

- Product description: www.gyros.com/products/overview.html
- Download images: www.gyros.com/news/press_material.html

About Frost & Sullivan Awards

Frost & Sullivan Awards are presented to companies in recognition of making an outstanding contribution to their respective industry or achieving a competitive or customer-based leading position in the market.

What is unique about Frost & Sullivan Awards?

This industry award is unique in that they are presented by a company dedicated to the analysis and forecasting of high-tech markets since its inception in 1961. Frost & Sullivan analysts conduct a rigorous selection methodology unmatched by any other firm.

What is the research methodology utilized in creating this award?

Frost & Sullivan utilizes its proprietary methodology to determine criteria for both the award and the award recipient. The first phase of our research process focuses on key industry challenges. Once these are determined, it is then possible to identify applicable measurements that address the challenges. The next phase, market research, is based on in-depth interviews with vendors, suppliers, and customers. One key criterion for the award is how well the company addressed each industry challenge.

More information about Frost & Sullivan’s Awards Program:

www.awards.frost.com

About Gyros AB

Gyros miniaturizes and integrates laboratory applications, enabling scientists to generate more information from less sample and to improve lab performance. Using our proprietary technology platform, we increase productivity by streamlining the many steps of conventional applications

into single, nanoliter scale procedures. Optimal environments are created for each application.

A Gyrolab microlaboratory, in the form of a compact disk, can process hundreds of samples in parallel, under the control of Gyrolab Workstation.

Our company will realize the full potential of the Gyros technology platform in the fields of drug discovery and diagnostics. Initial product offerings are focused towards the growing area of proteomics. Gyros has 65 employees working at its headquarters in Uppsala Science Park, Sweden and in sales offices in the USA and Europe.

For further information, visit www.gyros.com or contact:

Jan Würtz, President and CEO, Gyros AB

Tel: +46 (0)18 566 400

Mobile: +46 (0)70 592 5670

Email: jan.wurtz@gyros.com

Mats Bergström, Vice President, Marketing and Sales, Gyros AB

Tel: +46 (0)18 566 377

Mobile: +46-(0)70 536 33 11

Email: mats.bergstrom@gyros.com

Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.

Gyros, Gyrolab, Bioaffy and the Gyros logo are registered trademarks of Gyros AB.